Shenzhen Hepalink Pharmaceutical Group Co., Ltd. is a China-based pharmaceutical company specializing in the research, development, manufacturing and sale of heparin and related products. The company’s core product line centers on heparin sodium APIs (active pharmaceutical ingredients), low-molecular-weight heparins (LMWH) and specialty heparin derivatives. In addition to bulk heparin APIs, Hepalink produces a range of finished dosage forms such as heparin injections and protamine sulfate, serving hospitals, distributors and pharmaceutical companies.
Since its founding in the late 1990s in Shenzhen, Hepalink has grown to become one of the world’s leading suppliers of heparin and LMWH. The company operates multiple GMP-certified manufacturing facilities in China and holds regulatory approvals from major markets, including China’s NMPA, the U.S. FDA and the European Medicines Agency. Hepalink exports its products to more than 80 countries and regions, with significant markets in North America, Europe, Asia and Latin America, where it supports both generic and specialty anticoagulant therapies.
Beyond heparin APIs and formulations, Hepalink has expanded its R&D capabilities to include recombinant proteins, monoclonal antibodies and other biologics. The company collaborates with academic institutions and international partners to advance novel drug candidates and optimize production processes. With a focus on quality control, regulatory compliance and innovation, Shenzhen Hepalink continues to invest in research facilities and process development to support long-term growth in both domestic and global pharmaceutical markets.
AI Generated. May Contain Errors.
